KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has attracted significant investment activity from Venrock Healthcare Capital ...
JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price ...
MediPharm Labs Corp. ("MediPharm", "MediPharm Labs" or the "Company") has terminated the previously announced sale of its facility in Napanee, Ontario (the "Napanee Facility") to Kensana Health Inc. ( ...
Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term ...